QUALITY-CONTROL GUIDELINES FOR CEFDINIR, CEFEPIME, CEFETAMET, CEFMETAZOLE, CEFPODOXIME, CEFPROZIL, AND CLINAFLOXACIN (CI-960) FOR VARIOUS NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS SUSCEPTIBILITY TESTING METHODS

Several multilaboratory studies to determine quality control (QC) rang es for a variety of National Committee for Clinical Laboratory Standar ds (NCCLS) susceptibility tests are summarized. Replicate testing used multiple lots of media and antimicrobial disks in accordance with NCC LS recommendations, including the appropriate medium modifications for tests with Haemophilus spp. and Neisseria gonorrhoeae. QC ranges for MIC and disk diffusion testing of N. gonorrhoeae ATCC 49226 were propo sed for cefepime, cefetamet, cefmetazole, and cefpodoxime. Disk diffus ion QC ranges for Haemophilus influenzae ATCC 49247 or ATCC 49766 were recommended with cefepime, cefetamet (10- and 30-mug disks), cefmetaz ole, cefpodoxime, and cefprozil. Disk diffusion QC ranges for Staphylo coccus aureus ATCC 25923 and Escherichia coli ATCC 25922 with cefdinir and clinafloxacin and those for Pseudomonas aeruginosa ATCC 27853 wit h clinafloxacin were also proposed.